Telix Pharmaceuticals Ltd (TLX) Form 6-K — Aug 31, 2026
Telix Pharmaceuticals has appointed David Gill as Chair of its Board, effective immediately, succeeding Dr. Mark Nelson, who served as interim Chair and remains a Non-Executive Director. The transition was pre-planned: Gill joined the Telix Board in May 2026 as part of board expansion and succession planning with the stated intention of becoming Chair. Gill is a life sciences executive with more than 35 years of experience in senior general management and financial leadership, having served as CFO or President of publicly traded companies including EndoChoice Holdings, INC Research, and CTI Molecular Imaging.
Key figures
- Years experience new chair
- 35
- Illuccix commercial countries
- 22
- Pivotal stage pipeline assets
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.